Literature DB >> 12134259

Effect of the lower molecular capsule released from the cell surface of Bacillus anthracis on the pathogenesis of anthrax.

Sou-Ichi Makino1, Masahisa Watarai, Hyeng-Il Cheun, Toshikazu Shirahata, Ikuo Uchida.   

Abstract

Bacillus anthracis enters the body as an endospore, and encapsulation and toxin production occur after germination. Capsule is proposed to be an antiphagocytic factor, and toxin induces cytokine production for systemic shock. The dep gene, adjacent to the cap region for the encapsulation, degrades the high-molecular weight capsule (H-capsule) to the lower-molecular weight capsule (L-capsule), which releases into the culture supernatant. This study analyzed the biological function of the cap-dep region. The dep null mutant Sm-1, which formed H-capsule but not L-capsule, was avirulent. However, Sm-1 with an intact dep gene or with purified L-capsule recovered its pathogenicity. Sm-1 was subjected to phagocytosis by macrophages more easily than its parent strain, Sm, in vitro; in vivo, it cleared without L-capsule and grew well with L-capsule, which suggests that L-capsule is essential for in vivo multiplication. Moreover, a new name, capD, might be appropriate, because of the part of the cap operon involved in both polymerization and depolymerization of the capsule.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12134259     DOI: 10.1086/341299

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  37 in total

1.  atxA controls Bacillus anthracis capsule synthesis via acpA and a newly discovered regulator, acpB.

Authors:  Melissa Drysdale; Agathe Bourgogne; Susan G Hilsenbeck; Theresa M Koehler
Journal:  J Bacteriol       Date:  2004-01       Impact factor: 3.490

2.  Genome engineering in Bacillus anthracis using Cre recombinase.

Authors:  Andrei P Pomerantsev; Ramakrishnan Sitaraman; Craig R Galloway; Violetta Kivovich; Stephen H Leppla
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax.

Authors:  Melissa Drysdale; Sara Heninger; Julie Hutt; Yahua Chen; C Rick Lyons; Theresa M Koehler
Journal:  EMBO J       Date:  2004-12-16       Impact factor: 11.598

Review 4.  Bacterial Virulence Factors: Secreted for Survival.

Authors:  Aditya Kumar Sharma; Neha Dhasmana; Neha Dubey; Nishant Kumar; Aakriti Gangwal; Meetu Gupta; Yogendra Singh
Journal:  Indian J Microbiol       Date:  2016-11-05       Impact factor: 2.461

5.  Role of the protective antigen octamer in the molecular mechanism of anthrax lethal toxin stabilization in plasma.

Authors:  Alexander F Kintzer; Harry J Sterling; Iok I Tang; Ali Abdul-Gader; Andrew J Miles; B A Wallace; Evan R Williams; Bryan A Krantz
Journal:  J Mol Biol       Date:  2010-04-28       Impact factor: 5.469

Review 6.  The Bacillus cereus Group: Bacillus Species with Pathogenic Potential.

Authors:  Monika Ehling-Schulz; Didier Lereclus; Theresa M Koehler
Journal:  Microbiol Spectr       Date:  2019-05

7.  Human Innate Immune Cells Respond Differentially to Poly-γ-Glutamic Acid Polymers from Bacillus anthracis and Nonpathogenic Bacillus Species.

Authors:  Tanya M Jelacic; Wilson J Ribot; Jennifer Chua; Anne E Boyer; Adrian R Woolfitt; John R Barr; Arthur M Friedlander
Journal:  J Immunol       Date:  2020-01-13       Impact factor: 5.422

8.  Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis.

Authors:  Angelo Scorpio; Donald J Chabot; William A Day; David K O'brien; Nicholas J Vietri; Yoshifumi Itoh; Mansour Mohamadzadeh; Arthur M Friedlander
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

9.  Effect of Bacillus anthracis virulence factors on human dendritic cell activation.

Authors:  Andrew C Hahn; C Rick Lyons; Mary F Lipscomb
Journal:  Hum Immunol       Date:  2008-07-26       Impact factor: 2.850

10.  Treatment of experimental anthrax with recombinant capsule depolymerase.

Authors:  Angelo Scorpio; Steven A Tobery; Wilson J Ribot; Arthur M Friedlander
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.